China's EpimAb Hunts For Novel Biologics With Funding, Partnerships
Dr. Wu Chengbin, CEO and founder of Shanghai-based EpimAb Biotherapeutics, discusses with Scrip’s Brian Yang how the startup's platform will help companies develop next-generation bispecific antibodies.
You may also be interested in...
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
The world’s second-largest economy is fast moving away from reforms and open to a "dual circulation" model, focusing on domestic market consumption while reducing export-driven production. Executives and investors shared views at a conference on whether multinational pharma firms are still welcome in China and what opportunities may lie in the drastic policy shift.